Jianjun Gao
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (45)
Year:
2026
Year:
2025
Year:
2025
Background Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC). ICI is the standard first-line (1L) treatment of metastatic ccRCC, and there is unmet need for improved treatment outcomes after progression on ICI. We hypothesized that sitravatinib plus nivolumab would revert an immunosuppressive tumor microenvironment (TME) to improve clinical outcomes. Methods In this investigator-initiated, phase II, multicenter trial (NCT04904302), patients with progressive metastatic ccRCC after 1-2 lines of treatment were enrolled into 3 cohorts: (1) 1L nivolumab + ipilimumab, (2) 1L pembrolizumab + axitinib, (3) prior cabozantinib or lenvatinib and ICI. Starting dose of sitravatinib was 100 mg PO daily and nivolumab was 480 mg IV every 4 weeks. The co-primary endpoints were objective response rate (ORR) and disease control rate (DCR) at 24 weeks. The study was designed to enroll 88 patients with an interim analysis for futility in each cohort using a BOP2 design, but it was terminated early due to discontinuation of sitravatinib development. Results Fourteen patients were enrolled with 2 in cohort A, 6 in cohort B, and 6 in cohort C. Across all cohorts, the ORR was 15.4% (2/13, 1 not evaluable) and DCR at 24 weeks was 35.7% (5/14). DCR at 24 months was 63% for Cohort A + B and 0% for Cohort C. Median progression free survival was 5.5 mo [95% CI 3.8—not reached (NR)], and median overall survival was 13.3 mo (95% CI 8.77—NR). Six patients (42.9%) experienced a grade 3-4 adverse event (AE) and 2 patients (14.3%) experienced an immune-mediated AE. Conclusion In this small phase 2 trial with limited sample size due to early termination, sitravatinib plus nivolumab demonstrated a manageable safety profile and produced modest clinical benefit. The observed responses occurred in patients who did not receive prior treatment with cabozantinib or lenvatinib. (ClinicalTrials.gov Identifier: NCT04904302).
Year:
2025
Supplementary Figure S3 Clinical courses of MRD+ cases and tumor expression profiles in MRD lesions. (A) The expression of potential therapeutic targets and genes of interest in the tumor region of sample 3A, the MRD sample from Pt-10. (B) The clinical course of the other three MRD+ cases, as represented by dynamic changes of serum CA-125 level, along with H&E staining, pathology annotations of tumor and non-tumor regions, as well as the expression of potential therapeutic targets and genes of interest in the MRD samples.
Year:
2025
Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy (SLL) and ctDNA at the completion of first-line therapy. Experimental Design: Patients with high-grade epithelial ovarian cancer who had a complete clinical response to first-line therapy and underwent SLL and plasma collection for ctDNA were included. Progression-free survival (PFS) and overall survival (OS) were estimated based on MRD and clinicopathologic status. Spatial transcriptomics (GeoMx and Visium) and proteomics (CODEX) profiling were performed on serial samples from select patients. Results: Forty of 95 (42.1%) patients had surgically detected MRD, which was associated with worse PFS (median PFS 7.4 vs. 23.8 months; P P P = 0.013) in multivariable analysis. Among 44 patients who underwent SLL and had ctDNA testing, 34% (15/44) were ctDNA-positive, which was associated with worse PFS (6.4 vs. 28.1 months; P P = 0.008). We demonstrated the feasibility of spatial multiomics in studying MRD and their ability to provide hypothesis-generating observations, implicating the upregulation of the hypoxia signaling pathway, expression of multiple druggable targets ( CDK6 , GLS , MSLN , ERBB2 ), and immune exclusion in MRD lesions. Conclusions: Approximately half of patients in clinical remission after first-line therapy have assessable MRD, which can inform prognosis, therapeutic target discovery, and clinical trials.
Year:
2025
Supplementary Figure S4 Immune exclusion in the SLL sample 6B revealed by orthogonal spatial profiling. (A) CODEX profiling revealed two representative regions in the MRD sample (6B) of Pt-67. Region 1 located in the tumor margin where tumor cells interfaced with abundant CD8 T cells that demonstrated an exhausted state. This region was also enriched for interferon-stimulating signals. In contrast, region 2 represented tumor interior where very few CD8 T cells were observed. (B) Visium spatial profiling of the same sample as (A). CD8 T cell signals were detected in the tumor margin, which highly overlapped with the signals of immune checkpoint and interferon-stimulated genes.
Year:
2025
Supplementary Figure S2 Transcriptomic level comparisons of the tumor compartment between MRD and IDS samples using GeoMx data. (A) Volcano plot showing DEGs between the tumor compartment of MRD and IDS samples, with genes related to hypoxia signaling highlighted. (B) GSEA showing enriched pathways in the tumor compartment of MRD samples.
Year:
2025
Supplementary Figure S1 Clinical management of patients in the study cohort following SLL. *Many of these patients had the HRD assay performed retroactively on archival tissue and in this case, HRD status was not known in the upfront maintenance setting to guide therapy.
Year:
2025
Analysis of CD8+ cell infiltration at baseline in bone tumors and description of COMET analysis. A) Representative images captured by confocal microscope of CD8+ cell infiltration in bone tumors and quantification of CD8+ cell number; tumor (green, GFP), CD8+ cells (yellow), blood vessels (laminin, red), nuclei (blue, DAPI); dashed line, tumor edge; mean + SEM, n=3/group; dotted lines. B) Spatial definition of tumor edge; dashed line, tumor edge; dotted lines were draw at + 25 µm of distance from the tumor edge, that represents the tumor interface. C) A quantification of the % of CD8+ cells is shown, mean + SEM, n=3/group. D) Visual representation of experimental design (referred to Figure 4.). E, F) Representative images captured by confocal microscope of the distance (dotted line) between CD8+ cells (yellow) and the closest blood vessel (red, laminin) with quantification, mean + SEM, n=25-75/group. (F). G) Representation of step-by-step process of analysis of the immune infiltrate including tissue segmentation in VisioPharm. P values by one-way ANOVA with Tukey’s HSD post hoc test; p
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (42)
Matthew Campbell
Associate Professor
The University of Texas MD Anderson Cancer Center
Yesim Gokmen-Polar
Associate Professor
Emory University
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Katherine Kurnit
Assistant Professor
University of Chicago Medicine
Kaitlin J Basham
Assistant Professor
University of Utah
Nizar M Tannir
Professor and Deputy Chair
The University of Texas MD Anderson Cancer Center
Daniel Frigo
Scientific Director of Research
The University of Texas MD Anderson Cancer Center
Mingyao Li
Professor of Biostatistics, Digital Pathology, Statistics & Data Science
University of Pennsylvania
Roni Wilke
The University of Texas MD Anderson Cancer Center
Anil Sood
Professor
The University of Texas MD Anderson Cancer Center
Sanghoon Lee
Associate Professor
The University of Texas MD Anderson Cancer Center
Amir Jazaeri
Professor
The University of Texas MD Anderson Cancer Center
Edwin Roger Parra
Associate Professor
The University of Texas MD Anderson Cancer Center
Andrew Futreal
Chair and Professor
The University of Texas MD Anderson Cancer Center
Eleonora Dondossola
The University of Texas MD Anderson Cancer Center
Jeffrey How
Assistant Professor
The University of Texas MD Anderson Cancer Center
Yibo Dai
The University of Texas MD Anderson Cancer Center
Shannon Westin
The University of Texas MD Anderson Cancer Center
Paola A. Guerrero
Research Group Leader
The University of Texas MD Anderson Cancer Center
Gwyn Richardson
Professor
The University of Texas MD Anderson Cancer Center
Sangeeta Goswami
Associate Professor/ Joint Appointment
The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Stephanie Watowich
Vivian L. Smith Distinguished Chair in Immunology
The University of Texas MD Anderson Cancer Center
Sreyashi Basu
The University of Texas MD Anderson Cancer Center
Sunil Badve
Vice Chair/ Professor
Emory University
Dipen Maru
Professor
The University of Texas MD Anderson Cancer Center
Manoj Chelvanambi
The University of Texas MD Anderson Cancer Center
Pamela Soliman
Associate Professor
The University of Texas MD Anderson Cancer Center
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Xin Shelley Wang
Professor
The University of Texas MD Anderson Cancer Center
Nathaniel Wilson
Assistant Professor of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Minetta Liu
Research Collaborator, Professor
Mayo Clinic
Ying Yuan
Professor
The University of Texas MD Anderson Cancer Center
Kai Wucherpfennig
Professor and Department Chair
Dana-Farber Cancer Institute
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
Ken Chen
Professor
The University of Texas MD Anderson Cancer Center
Humam Kadara
The University of Texas MD Anderson Cancer Center
Lulu Shang
Assistant Professor
The University of Texas MD Anderson Cancer Center
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
Jared Burks
Professor
The University of Texas MD Anderson Cancer Center
Yinghong Wang
Associate Professor
The University of Texas MD Anderson Cancer Center
David Boruta
Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.